|
|
|
| All about Peyronie's disease |
| Ahmed A. Hussein, Amjad Alwaal, Tom F.Lue
|
1. Department of Urology, University of California, San Francisco, CA, USA;
2. Department of Urology, Cairo University, Egypt;
3. Department of Urology, King Abdul Aziz University, Saudi Arabia |
|
|
|
|
Abstract Peyronie's disease (PD) is an acquired connective tissue disorder of the tunica albuginea of the corpus cavernosum, characterized by excessive fibrosis and plaque formation. PD can result in significant physical and psychological morbidity; as it may prevent intercourse and cause adverse impacts on partner relationships. The exact etiology and pathophysiology remain unclear, and many misconceptions about the disease associations, course and treatment exist. The disease has two distinct stages. The acute stage is characterized by pain, and disease may progress during this stage. Non-surgical managements at this stage aim to alleviate pain and stabilize the disease. Results for non-surgical treatment are often conflicting. The chronic stage occurs 6-12 months later, where pain disappears and the deformity stabilizes. Surgical treatment is reserved for significant deformity or with inability to penetrative intercourse. The choice of the surgical technique depends on the length of the penis, degree of deformity, erectile function, patients' expectations and surgeon's preference.
|
|
Published: 30 April 2015
|
|
Corresponding Authors:
Amjad Alwaal
E-mail: amjadwal@yahoo.com
|
|
|
| [1] |
Ralph D, Gonzalez-Cadavid N, Mirone V, Perovic S, Sohn M, Usta M, et al. The management of Peyronie's disease: evidence-based 2010 guidelines. J Sex Med 2010;7:2359-74.
|
| [2] |
Bella AJ, Perelman MA, Brant WO, Lue TF. Peyronie's disease (CME). J Sex Med 2007;4:1527-38.
|
| [3] |
Smith JF, Walsh TJ, Conti SL, Turek P, Lue T. Risk factors for emotional and relationship problems in Peyronie's disease. J Sex Med 2008;5:2179-84.
|
| [4] |
Garaffa G, Trost LW, Serefoglu EC, Ralph D, Hellstrom WJ. Understanding the course of Peyronie's disease. Int J Clin Pract 2013;67:781-8.
|
| [5] |
Mulhall JP, Creech SD, Boorjian SA, Ghaly S, Kim ED, Moty A, et al. Subjective and objective analysis of the prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening. J Urol 2004;171:2350-3.
|
| [6] |
Tefekli A, Kandirali E, Erol H, Alp T, Koksal T, Kadioglu A. Peyronie's disease in men under age 40: characteristics and outcome. Int J Impot Res 2001;13:18-23.
|
| [7] |
Tal R, Hall MS, Alex B, Choi J, Mulhall JP. Peyronie's disease in teenagers. J Sex Med 2012;9:302-8.
|
| [8] |
Kadioglu A, Tefekli A, Erol B, Oktar T, Tunc M, Tellaloglu S. A retrospective review of 307 men with Peyronie's disease. J Urol 2002;168:1075-9.
|
| [9] |
Tal R, Heck M, Teloken P, Siegrist T, Nelson CJ, Mulhall JP. Peyronie's disease following radical prostatectomy: incidence and predictors. J Sex Med 2010;7:1254-61.
|
| [10] |
European Association of Urology. Guidelines on Penile Curvature. 2014. available online at: http://uroweb.org/fileadmin/guidelines/Guidelines_2014_5_June_2014.pdf
|
| [11] |
Rhoden EL, Riedner CE, Fuchs SC, Ribeiro EP, Halmenschlager G. A cross-sectional study for the analysis of clinical, sexual and laboratory conditions associated to Peyronie's disease. J Sex Med 2010;7:1529-37.
|
| [12] |
El-Sakka AI, Tayeb KA. Peyronie's disease in diabetic patients being screened for erectile dysfunction. J Urol 2005;174:1026-30.
|
| [13] |
Arafa M, Eid H, El-Badry A, Ezz-Eldine K, Shamloul R. The prevalence of Peyronie's disease in diabetic patients with erectile dysfunction. Int J Impot Res 2007;19:213-7.
|
| [14] |
Nelson CJ, Diblasio C, Kendirci M, Hellstrom W, Guhring P, Mulhall JP. The chronology of depression and distress in men with Peyronie's disease. J Sex Med 2008;5:1985-90.
|
| [15] |
Rosen R, Catania J, Lue T, Althof S, Henne J, Hellstrom W, et al. Impact of Peyronie's disease on sexual and psychosocial functioning: qualitative findings in patients and controls. J Sex Med 2008;5:1977-84.
|
| [16] |
Gelbard MK, Dorey F, James K. The natural history of Peyronie's disease. J Urol 1990;144:1376-9.
|
| [17] |
Mulhall JP, Schiff J, Guhring P. An analysis of the natural history of Peyronie's disease. J Urol 2006;175:2115-8.
|
| [18] |
Devine CJ Jr, Somers KD, Jordan SG, Schlossberg SM. Proposal: trauma as the cause of the Peyronie's lesion. J Urol 1997;157:285-90.
|
| [19] |
Gonzalez-Cadavid NF, Rajfer J. Mechanisms of disease: new insights into the cellular and molecular pathology of Peyronie's disease. Nat Clin Pract Urol 2005;2:291-7.
|
| [20] |
Devine CJ Jr. International Conference on Peyronie's disease advances in basic and clinical research. March 17-19, 1993. Introduction. J Urol 1997;157:272-5.
|
| [21] |
Gonzalez-Cadavid NF, Magee TR, Ferrini M, Qian A, Vernet D, Rajfer J. Gene expression in Peyronie's disease. Int J Impot Res 2002;14:361-74.
|
| [22] |
Jalkut M, Gonzalez-Cadavid N, Rajfer J. New discoveries in the basic science understanding of Peyronie's disease. Curr Urol Rep 2004;5:478-84.
|
| [23] |
Piao S, Ryu JK, Shin HY, Zhang L, Song SU, Han JY, et al. Repeated intratunical injection of adenovirus expressing transforming growth factor-beta1 in a rat induces penile curvature with tunical fibrotic plaque: a useful model for the study of Peyronie's disease. Int J Androl 2008;31:346-53.
|
| [24] |
Ryu JK, Piao S, Shin HY, Choi MJ, Zhang LW, Jin HR, et al. IN-1130, a novel transforming growth factor-beta type I receptor kinase (activin receptor-like kinase 5) inhibitor, promotes regression of fibrotic plaque and corrects penile curvature in a rat model of Peyronie's disease. J Sex Med 2009;6:1284-96.
|
| [25] |
El-Sakka AI, Hassoba HM, Pillarisetty RJ, Dahiya R, Lue TF. Peyronie's disease is associated with an increase in transforming growth factor-beta protein expression. J Urol 1997;158:1391-4.
|
| [26] |
Nugteren HM, Nijman JM, de Jong IJ, van Driel MF. The association between Peyronie's and Dupuytren's disease. Int J Impot Res 2011;23:142-5.
|
| [27] |
Berookhim BM, Choi J, Alex B, Mulhall JP. Deformity stabilization and improvement in men with untreated Peyronie's disease. BJU Int 2014;113:133-6.
|
| [28] |
Vernet D, Nolazco G, Cantini L, Magee TR, Qian A, Rajfer J, et al. Evidence that osteogenic progenitor cells in the human tunica albuginea may originate from stem cells: implications for peyronie disease. Biol Reprod 2005;73:1199-210.
|
| [29] |
Levine L, Rybak J, Corder C, Farrel MR. Peyronie's disease plaque calcification--prevalence, time to identification, and development of a new grading classification. J Sex Med 2013;10:3121-8.
|
| [30] |
Breyer BN, Shindel AW, Huang YC, Eisenberg ML, Weiss DA, Lue TF, et al. Are sonographic characteristics associated with progression to surgery in men with Peyronie's disease? J Urol 2010;183:1484-8.
|
| [31] |
Bekos A, Arvaniti M, Hatzimouratidis K, Moysidis K, Tzortzis V, Hatzichristou D. The natural history of Peyronie's disease: an ultrasonography-based study. Eur Urol 2008;53:644-50.
|
| [32] |
Larsen SM, Levine LA. Peyronie's disease: review of nonsurgical treatment options. Urol Clin N Am 2011;38:195-205.
|
| [33] |
Chung E, Yan H, De Young L, Brock GB. Penile Doppler sonographic and clinical characteristics in Peyronie's disease and/or erectile dysfunction: an analysis of 1500 men with male sexual dysfunction. BJU Int 2012;110:1201-5.
|
| [34] |
Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997;49:822-30.
|
| [35] |
Kadioglu A, Tefekli A, Erol H, Cayan S, Kandirali E. Color Doppler ultrasound assessment of penile vascular system in men with Peyronie's disease. Int J Impot Res 2000;12:263-7.
|
| [36] |
Lopez JA, Jarow JP. Penile vascular evaluation of men with Peyronie's disease. J Urol 1993;149:53-5.
|
| [37] |
Porst H, Vardi Y, Akkus E, Melman A, Park NC, Seftel AD, et al. Standards for clinical trials in male sexual dysfunctions. J Sex Med 2010;7:414-44.
|
| [38] |
Gur S, Limin M, Hellstrom WJ. Current status and new developments in Peyronie's disease: medical, minimally invasive and surgical treatment options. Expert Opin Pharmacother 2011;12:931-44.
|
| [39] |
Griffiths MR, Priestley GC. A comparison of morphoea and lichen sclerosus et atrophicus in vitro: the effects of para-aminobenzoate on skin fibroblasts. Acta Derm Venereol 1992;72:15-8.
|
| [40] |
Shah P, Green N, Adib R. A multicentre double-blind controlled clinical trial of potassium para-amino-benzoate (POTABA1) in Peyronie's disease. Progr Reprod Biol Med 1983;1:61-7.
|
| [41] |
Weidner W, Hauck EW, Schnitker J; Peyronie's Disease Study Group of Andrological Group of German U. Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie's disease: a prospective, placebo-controlled, randomized study. Eur Urol 2005;47:530-6.
|
| [42] |
Teloken C, Rhoden EL, Grazziotin TM, Ros CT, Sogari PR, Souto CA. Tamoxifen versus placebo in the treatment of Peyronie's disease. J Urol 1999;162:2003-5.
|
| [43] |
Akkus E, Carrier S, Rehman J, Breza J, Kadioglu A, Lue TF. Is colchicine effective in Peyronie's disease? A pilot study. Urology 1994;44:291-5.
|
| [44] |
Kadioglu A, Tefekli A, Koksal T, Usta M, Erol H. Treatment of Peyronie's disease with oral colchicine: long-term results and predictive parameters of successful outcome. Int J Impot Res 2000;12:169-75.
|
| [45] |
Prieto Castro RM, Leva Vallejo ME, Regueiro Lopez JC, Anglada Curado FJ, Alvarez Kindelan J, Requena Tapia MJ. Combined treatment with vitamin E and colchicine in the early stages of Peyronie's disease. BJU Int 2003;91:522-4.
|
| [46] |
Netticadan T, Yu L, Dhalla NS, Panagia V. Palmitoyl carnitine increases intracellular calcium in adult rat cardiomyocytes. J Mol Cell Cardiol 1999;31:1357-67.
|
| [47] |
Biagiotti G, Cavallini G. Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie's disease: a preliminary report. BJU Int 2001;88:63-7.
|
| [48] |
Lin G, Shindel AW, Banie L, Ning H, Huang YC, Liu G, et al. Pentoxifylline attenuates transforming growth factorbeta1- stimulated elastogenesis in human tunica albugineaderived fibroblasts part 2: Interference in a TGF-beta1/Smaddependent mechanism and downregulation of AAT1. J Sex Med 2010;7:1787-97.
|
| [49] |
Smith JF, Shindel AW, Huang YC, Clavijo RI, Flechner L, Breyer BN, et al. Pentoxifylline treatment and penile calcifications in men with Peyronie's disease. Asian J Androl 2011;13:322-5.
|
| [50] |
Aviado DM, Porter JM. Pentoxifylline: a new drug for the treatment of intermittent claudication. Mechanism of action, pharmacokinetics, clinical efficacy and adverse effects. Pharmacotherapy 1984; 4:297-307.
|
| [51] |
Ferrini MG, Kovanecz I, Nolazco G, Rajfer J, Gonzalez-Cadavid NF. Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie's disease. BJU Int 2006;97:625-33.
|
| [52] |
Palmieri A, Imbimbo C, Creta M, Verze P, Fusco F, Mirone V. Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie's disease and erectile dysfunction: results from a prospective randomized trial. Int J Androl 2012;35:190-5.
|
| [53] |
Safarinejad MR. Safety and efficacy of coenzyme Q10 supplementation in early chronic Peyronie's disease: a doubleblind, placebo-controlled randomized study. Int J Impot Res 2010; 22:298-309.
|
| [54] |
Safarinejad MR. Efficacy and safety of omega-3 for treatment of early-stage Peyronie's disease: A prospective, randomized, doubleblind placebo-controlled study. J Sex Med 2009;6:1743-54.
|
| [55] |
Jordan GH. The use of intralesional clostridial collagenase injection therapy for Peyronie's disease: a prospective, single-center, nonplacebo- controlled study. J Sex Med 2008;5:180-7.
|
| [56] |
Hellstrom WJG. Medical Management of Peyronie's Disease. J Androl 2009;30:397-405.
|
| [57] |
Gelbard MK, James K, Riach P, Dorey F. Collagenase versus placebo in the treatment of Peyronie's disease: a double-blind study. J Urol 1993;149:56-8.
|
| [58] |
Desanctis PN, Furey CA Jr. Steroid injection therapy for Peyronie's disease: a 10-year summary and review of 38 cases. J Urol 1967;97:114-6.
|
| [59] |
Mulhall JP, Anderson MS, Lubrano T, Shankey TV. Peyronie's disease cell culture models: phenotypic, genotypic and functional analyses. Int J Impot Res 2002;14:397-405.
|
| [60] |
Rehman J, Benet A, Melman A. Use of intralesional verapamil to dissolve Peyronie's disease plaque: a long-term single-blind study. Urology 1998;51:620-6.
|
| [61] |
Levine LA, Goldman KE, Greenfield JM. Experience with intraplaque injection of verapamil for Peyronie's disease. J Urol 2002;168:621-6.
|
| [62] |
Duncan MR, Berman B, Nseyo UO. Regulation of the proliferation and biosynthetic activities of cultured human Peyronie's disease fibroblasts by interferons-alpha, -beta and -gamma. Scand J Urol Nephrol 1991;25:89-94.
|
| [63] |
Kendirci M, Usta MF, Matern RV, Nowfar S, Sikka SC, Hellstrom WJ. The impact of intralesional interferon alpha-2b injection therapy on penile hemodynamics in men with Peyronie's disease. J Sex Med 2005;2:709-15.
|
| [64] |
Hellstrom WJ, Kendirci M, Matern R, Cockerham Y, Myers L, Sikka SC, et al. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie's disease. J Urol 2006;176:394-8.
|
| [65] |
Fitch WP 3rd, Easterling WJ, Talbert RL, Bordovsky MJ, Mosier M. Topical verapamil HCl, topical trifluoperazine, and topical magnesium sulfate for the treatment of Peyronie's disease--a placebo-controlled pilot study. J Sex Med 2007;4:477-84.
|
| [66] |
Di Stasi SM, Giannantoni A, Capelli G, Jannini EA, Virgili G, Storti L, et al. Transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease. BJU Int 2003;91:825-9.
|
| [67] |
Greenfield JM, Shah SJ, Levine LA. Verapamil versus saline in electromotive drug administration for Peyronie's disease: a doubleblind, placebo controlled trial. J Urol 2007;177:972-5.
|
| [68] |
Husain J, Lynn NN, Jones DK, Collins GN, O'Reilly PH. Extracorporeal shock wave therapy in the management of Peyronie's disease: initial experience. BJU Int 2000;86:466-8.
|
| [69] |
Palmieri A, Imbimbo C, Longo N, Fusco F, Verze P, Mangiapia F,et al. A first prospective, randomized, double-blind, placebo-controlled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie's disease. Eur Urol 2009;56:363-9.
|
| [70] |
Chitale S, Morsey M, Swift L, Sethia K. Limited shock wave therapy vs sham treatment in men with Peyronie's disease: results of a prospective randomized controlled double-blind trial. BJU Int 2010;106:1352-6.
|
| [71] |
Bailey AJ, Tarlton JF, Van der Stappen J, Sims TJ, Messina A. The continuous elongation technique for severe Dupuytren's disease. A biochemical mechanism. J Hand Surg Br 1994;19:522-7.
|
| [72] |
Levine LA, Newell M, Taylor FL. Penile traction therapy for treatment of Peyronie's disease: a single-center pilot study. J Sex Med 2008;5:1468-73.
|
| [73] |
Raheem AA, Garaffa G, Raheem TA, Dixon M, Kayes A, Christopher N, et al. The role of vacuum pump therapy to mechanically straighten the penis in Peyronie's disease. BJU Int 2010;106:1178-80.
|
| [74] |
Kendirci M, Hellstrom WJ. Critical analysis of surgery for Peyronie's disease. Curr Opin Urol 2004;14:381-8.
|
| [75] |
Dukic I, Thakare N, Pearce I, Payne SR. Should assessment of penetrative sexual activity be used as the treatment arbiter in the management of Peyronie's disease? Int J Impot Res 2011;23:70-5.
|
| [76] |
Langston JP, Carson CC 3rd. Peyronie disease: plication or grafting.Urol Clin N Am 2011;38:207-16.
|
| [77] |
Mulhall J, Anderson M, Parker M. A surgical algorithm for men with combined Peyronie's disease and erectile dysfunction: functional and satisfaction outcomes. J Sex Med 2005;2:132-8.
|
| [78] |
Nesbit RM. Congenital curvature of the phallus: report of three cases with description of corrective operation. J Urol 1965;93:230-2.
|
| [79] |
Pryor JP, Fitzpatrick JM. A new approach to the correction of the penile deformity in Peyronie's disease.J Urol 1979;122:622-3.
|
| [80] |
Pryor JP. Correction of penile curvature and Peyronie's disease: why I prefer the Nesbit technique. Int J Impot Res 1998;10:129-31.
|
| [81] |
Ralph DJ, al-Akraa M, Pryor JP. The Nesbit operation for Peyronie's disease: 16-year experience. J Urol 1995;154:1362-3.
|
| [82] |
Savoca G, Trombetta C, Ciampalini S, De Stefani S, Buttazzi L, Belgrano E. Long-term results with Nesbit's procedure as treatment of Peyronie's disease. Int J Impot Res 2000;12:289-93.
|
| [83] |
Rehman J, Benet A, Minsky LS, Melman A. Results of surgical treatment for abnormal penile curvature: Peyronie's disease and congenital deviation by modified Nesbit plication (tunical shaving and plication). J Urol 1997;157:1288-91.
|
| [84] |
Dalkin BL, Carter MF. Venogenic impotence following dermal graft repair for Peyronie's disease. J Urol 1991;146:849-51.
|
| [85] |
Kadioglu A, Akman T, Sanli O, Gurkan L, Cakan M, Celtik M. Surgical treatment of Peyronie's disease: a critical analysis. Eur Urol 2006;50:235-48.
|
| [86] |
Das S. Peyronie's disease: excision and autografting with tunica vaginalis. J Urol 1980;124:818-9.
|
| [87] |
Chun JL, McGregor A, Krishnan R, Carson CC. A comparison of dermal and cadaveric pericardial grafts in the modified Horton- Devine procedure for Peyronie's disease. J Urol 2001;166:185-8.
|
| [88] |
Lentz AC, Carson CC 3rd. Peyronie's surgery: graft choices and outcomes. Curr Urol Rep 2009;10:460-7.
|
| [89] |
Knoll LD. Use of porcine small intestinal submucosal graft in the surgical management of Peyronie's disease. Urology 2001;57:753-7.
|
| [90] |
Wilson SK. Surgical techniques: modeling technique for penile curvature. J Sex Med 2007;4:231-4.
|
| [91] |
Shindel AW. Sexual dysfunction: the potential of stem cell therapy for Peyronie disease. Nat Rev Urol 2013;10:8-9.
|
| [92] |
Lin CS, Lin G, Lue TF. Allogeneic and xenogeneic transplantation of adipose-derived stem cells in immunocompetent recipients without immunosuppressants. Stem Cells Dev 2012;21:2770-8.
|
| [93] |
Chamberlain G, Fox J, Ashton B, Middleton J. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells 2007;25:2739-49.
|
| [94] |
Zhang H, Ning H, Banie L, Wang G, Lin G, Lue TF, et al. Adipose tissue-derived stem cells secrete CXCL5 cytokine with chemoattractant and angiogenic properties. Biochem Biophys Res Commun 2010;402:560-4.
|
| [95] |
Castiglione F, Hedlund P, Van der Aa F, Bivalacqua TJ, Rigatti P, Van Poppel H, et al. Intratunical injection of human adipose tissuederived stem cells prevents fibrosis and is associated with improved erectile function in a rat model of Peyronie's disease. Eur Urol 2013;63:551-60.
|
| No related articles found! |
|
|
|
|
